DGDaniel Grun

Daniel Grun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel Grun has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Gautam Adhikary

    Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland

    8 shared publications
  • Richard L. Eckert

    Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland

    8 shared publications
  • Matthew L. Fisher

    Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland

    6 shared publications
  • Candace Kerr

    Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland

    5 shared publications
  • Wen Xu

    Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland

    3 shared publications
  • Sivaprakasam Balasubramanian

    Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, 108 N. Greene Street, Baltimore, MD 21201, USA

    2 shared publications

Latest Publications

  • Open Access

    Transglutaminase 2 Is a Direct Target Gene of YAP-TAZ—Response

    by Matthew L. Fisher, Gautam Adhikary, Candace Kerr, Daniel Grun, Richard L. Eckert

    Transglutaminase 2 (TG2) is an important cancer stem cell survival protein (1–4). Our recent article described a novel transglutaminase 2 (TG2) signaling pathway whereby TG2 enhances cancer stem cell survival, spheroid formation, Matrigel invasion, and tumor formation in squamous cell carcinoma (5). We showed that TG2 triggers these events by activating an integrin, FAK, Src, PI3K signaling cascade that phosphorylates PDK1, causing it to dissociate from LATS1 to inhibit LATS1 activity. Inactivation of LATS1 leads to accumulation of nonphosphorylated YAP1, which then interacts with and stabilizes ΔNp63α, which drives the cancer stem cell phenotype (5). Hong and colleagues, in a letter to the editor, noted that our article did not describe regulation of TG2 by YAP1 in SCC-13 and HaCaT epidermis-derived cancer cells (5). In particular, we did not observe a change in TG2 level in squamous cell carcinoma cells expressing YAP(S127A), a constitutively active form of YAP1, or in cells treated with YAP1-siRNA. This is in contrast to their observation that YAP1 and TAZ interact with the TG2 promoter to regulate TG2 mRNA and protein level in MCF10A, HaCaT, and HCT116 cells (6). Although we have not studied the impact of YAP1 or TAZ on TG2 gene expression, we can confirm that TG2 is regulated by YAP1 and TAZ in some cell lines. For example, Fig. 1 shows a reduction in TG2 level in MCF-7 cells following treatment with YAP1 or TAZ-specific siRNA and confirms that this is associated with reduced spheroid formation. Thus, we conclude based on these findings that TG2 can be regulated by YAP1 and TAZ, but we further propose that this may depend upon the cell type and the cellular environment.See the original Letter to the Editor, p. 4734No potential conflicts of interest were disclosed.This work was supported by grants from the NIH (RLE - CA131074 and CA184027).


  • Open Access

    Sulforaphane reduces YAP/∆Np63α signaling to reduce cancer stem cell survival and tumor formation

    by Matthew L. Fisher, Nicholas Ciavattone, Daniel Grun, Gautam Adhikary, Richard L. Eckert

    Epidermal squamous cell carcinoma (SCC) is among the most common cancers. SCC can be treated by surgical excision, but recurrence of therapy-resistant disease is a major problem. We recently showed that YAP1, the Hippo signaling transcription adaptor protein, and ∆Np63α, a key epidermal stem cell survival protein, form a complex to drive epidermal cancer stem cell survival. In the present study, we demonstrate that YAP1 and ∆Np63α are important sulforaphane cancer prevention targets. We show that sulforaphane treatment increases YAP1 phosphorylation and proteolytic degradation. The loss of YAP1 is associated with a reduction in ∆Np63α level and a reduction in ECS cell survival, spheroid formation, invasion and migration. Loss of YAP1 and ∆Np63α is mediated by the proteasome and can be inhibited by lactacystin treatment. YAP1 or ∆Np63α knockdown replicates the responses to sulforaphane, and restoration of YAP1 or ∆Np63α antagonizes sulforaphane action. Sulforaphane suppresses ECS cell tumor formation and this is associated with reduced levels of YAP1 and ∆Np63α. These studies suggest that YAP1 and ∆Np63α may be important sulforaphane cancer preventive targets in epidermal squamous cell carcinoma.


  • Open Access

    Sulforaphane suppresses PRMT5/MEP50 function in epidermal squamous cell carcinoma leading to reduced tumor formation

    by Kamalika Saha, Matthew L Fisher, Gautam Adhikary, Daniel Grun, Richard L Eckert

    Protein arginine methyltransferase 5 (PRMT5) cooperates with methylosome protein 50 (MEP50) to arginine methylate histone H3 and H4 to silence gene expression, and increased PRMT5 activity is associated with enhanced cancer cell survival. We have studied the role of PRMT5 and MEP50 in epidermal squamous cell carcinoma. We show that knockdown of PRMT5 or MEP50 results in reduced H4R3me2s formation, and reduced cell proliferation, invasion, migration and tumor formation. We further show that treatment with sulforaphane (SFN), a cancer preventive agent derived from cruciferous vegetables, reduces PRMT5 and MEP50 level and H4R3me2s formation, and this is associated with reduced cell proliferation, invasion and migration. The SFN-dependent reduction in PRMT5 and MEP50 level requires proteasome activity. Moreover, SFN-mediated responses are partially reversed by forced PRMT5 or MEP50 expression. SFN treatment of tumors results in reduced MEP50 level and H4R3me2s formation, confirming that that SFN impacts this complex in vivo. These studies suggest that the PRMT5/MEP50 is required for tumor growth and that reduced expression of this complex is a part of the mechanism of SFN suppression of tumor formation.


  • Open Access

    Transglutaminase Interaction with α6/β4-Integrin Stimulates YAP1-Dependent ΔNp63α Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation

    by Matthew L. Fisher, Candace Kerr, Gautam Adhikary, Dan Grun, Wen Xu, Jeffrey W. Keillor, Richard L. Eckert

    Transglutaminase 2 (TG2) expression is required for epidermal squamous cell carcinoma cancer stem cell survival. However, the molecular signaling mechanisms triggered by TG2 that mediate this survival action are not well understood. Here we show that TG2 is constitutively expressed in ECS cells, where it interacts with α6/β4 integrin to stimulate FAK and Src signaling, leading to PI3K activation of phosphoinositide-dependent kinase 1 (PDK1). PDK1 inhibits Hippo signaling, leading to enhanced nuclear accumulation of YAP1, which interacted with and stabilized ΔNp63α to enhance epidermal squamous cell carcinoma spheroid formation, invasion, and migration. Overall, these findings suggest that constitutive TG2 expression results in stabilization of ΔNp63α, leading to maintenance of cancer stem cell properties and enhanced tumor formation. Cancer Res; 76(24); 7265–76. ©2016 AACR.


  • VEGF-A acts via neuropilin-1 to enhance epidermal cancer stem cell survival and formation of aggressive and highly vascularized tumors

    by D Grun, G Adhikary, R L Eckert

    We identify a limited subpopulation of epidermal cancer stem cells (ECS cells), in squamous cell carcinoma, that form rapidly growing, invasive and highly vascularized tumors, as compared with non-stem cancer cells. These ECS cells grow as non-attached spheroids, and display enhanced migration and invasion. We show that ECS cell-produced vascular endothelial growth factor (VEGF)-A is required for the maintenance of this phenotype, as knockdown of VEGF-A gene expression or treatment with VEGF-A-inactivating antibody reduces these responses. In addition, treatment with bevacizumab reduces tumor vascularity and growth. Surprisingly, the classical mechanism of VEGF-A action via interaction with VEGF receptors does not mediate these events, as these cells lack VEGFR1 and VEGFR2. Instead, VEGF-A acts via the neuropilin-1 (NRP-1) co-receptor. Knockdown of NRP-1 inhibits ECS cell spheroid formation, invasion and migration, and attenuates tumor formation. These studies suggest that VEGF-A acts via interaction with NRP-1 to trigger intracellular events leading to ECS cell survival and formation of aggressive, invasive and highly vascularized tumors.


  • The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane

    by Matthew L. Fisher, Gautam Adhikary, Dan Grun, David M. Kaetzel, Richard L. Eckert

    Melanoma is a metastatic cancer associated with poor survival. Here, we study a subpopulation of melanoma cancer cells displaying melanoma cancer stem cell (MCS cells) properties including elevated expression of stem cell markers, increased ability to survive as spheroids, and enhanced cell migration and invasion. We show that the Ezh2 stem cell survival protein is enriched in MCS cells and that Ezh2 knockdown or treatment with small molecule Ezh2 inhibitors, GSK126 or EPZ‐6438, reduces Ezh2 activity. This reduction is associated with a reduced MCS cell spheroid formation, migration, and invasion. Moreover, the diet‐derived cancer prevention agent, sulforaphane (SFN), suppresses MCS cell survival and this is associated with loss of Ezh2. Forced expression of Ezh2 partially reverses SFN suppression of MCS cell spheroid formation, migration, and invasion. A375 melanoma cell‐derived MCS cells form rapidly growing tumors in immune‐compromised mice and SFN treatment of these tumors reduces tumor growth and this is associated with reduced Ezh2 level and H3K27me3 formation, reduced matrix metalloproteinase expression, increased TIMP3 expression and increased apoptosis. These studies identify Ezh2 as a MCS cell marker and cancer stem cell prevention target, and suggest that SFN acts to reduce melanoma tumor formation via a mechanism that includes suppression of Ezh2 function.


  • Transglutaminase is a tumor cell and cancer stem cell survival factor

    by Richard L. Eckert, Matthew L. Fisher, Dan Grun, Gautam Adhikary, Wen Xu, Candace Kerr

    Recent studies indicate that cancer cells express elevated levels of type II transglutaminase (TG2), and that expression is further highly enriched in cancer stem cells derived from these cancers. Moreover, elevated TG2 expression is associated with enhanced cancer stem cell marker expression, survival signaling, proliferation, migration, invasion, integrin‐mediated adhesion, epithelial–mesenchymal transition, and drug resistance. TG2 expression is also associated with formation of aggressive and metastatic tumors that are resistant to conventional therapeutic intervention. This review summarizes the role of TG2 as a cancer cell survival factor in a range of tumor types, and as a target for preventive and therapeutic intervention. The literature supports the idea that TG2, in the closed/GTP‐binding/signaling conformation, drives cancer cell and cancer stem cell survival, and that TG2, in the open/crosslinking conformation, is associated with cell death.


  • Open Access

    Survival of skin cancer stem cells requires the Ezh2 polycomb group protein

    by Gautam Adhikary, Daniel Grun, Sivaprakasam Balasubramanian, Candace Kerr, Jennifer M. Huang, Richard L. Eckert

    Polycomb group proteins, including Ezh2, are important candidate stem cell maintenance proteins in epidermal squamous cell carcinoma. We previously showed that epidermal cancer stem cells (ECS cells) represent a minority of cells in tumors, are highly enriched in Ezh2 and drive aggressive tumor formation. We now show that Ezh2 is required for ECS cell survival, migration, invasion and tumor formation and that this is associated with increased histone H3 trimethylation on lysine 27, a mark of Ezh2 action. We also show that Ezh2 knockdown or treatment with Ezh2 inhibitors, GSK126 or EPZ-6438, reduces Ezh2 level and activity, leading to reduced ECS cell spheroid formation, migration, invasion and tumor growth. These studies indicate that epidermal squamous cell carcinoma cells contain a subpopulation of cancer stem (tumor-initiating) cells that are enriched in Ezh2, that Ezh2 is required for optimal ECS cell survival and tumor formation and that treatment with Ezh2 inhibitors may be a strategy for reducing ECS cell survival and suppressing tumor formation.


  • Open Access

    Identification of a Population of Epidermal Squamous Cell Carcinoma Cells with Enhanced Potential for Tumor Formation

    by Gautam Adhikary, Dan Grun, Candace Kerr, Sivaprakasam Balasubramanian, Ellen A. Rorke, Mohan Vemuri, Shayne Boucher, Jackie R. Bickenbach, Thomas Hornyak, Wen Xu, et al.

    Epidermal squamous cell carcinoma is among the most common cancers in humans. These tumors are comprised of phenotypically diverse populations of cells that display varying potential for proliferation and differentiation. An important goal is identifying cells from this population that drive tumor formation. To enrich for tumor-forming cells, cancer cells were grown as spheroids in non-attached conditions. We show that spheroid-selected cells form faster growing and larger tumors in immune-compromised mice as compared to non-selected cells. Moreover, spheroid-selected cells gave rise to tumors following injection of as few as one hundred cells, suggesting these cells have enhanced tumor-forming potential. Cells isolated from spheroid-selected tumors retain an enhanced ability to grow as spheroids when grown in non-attached culture conditions. Thus, these tumor-forming cells retain their phenotype following in vivo passage as tumors. Detailed analysis reveals that spheroid-selected cultures are highly enriched for expression of epidermal stem cell and embryonic stem cell markers, including aldehyde dehydrogenase 1, keratin 15, CD200, keratin 19, Oct4, Bmi-1, Ezh2 and trimethylated histone H3. These studies indicate that a subpopulation of cells that possess stem cell-like properties and express stem cell markers can be derived from human epidermal cancer cells and that these cells display enhanced ability to drive tumor formation.